Arcus Biosciences Announces Promising Initial Data for Casdatifan Plus Cabozantinib in Metastatic Kidney Cancer, Prepares to Launch Phase 3 PEAK-1 Study

Reuters

06-01

Arcus Biosciences Announces Promising Initial Data for Casdatifan Plus Cabozantinib in Metastatic Kidney Cancer, Prepares to Launch Phase 3 PEAK-1 Study

Arcus Biosciences Inc. has announced initial data from the ARC-20 study, which evaluated the combination of casdatifan and cabozantinib in patients with metastatic kidney cancer. The study reported a confirmed overall response rate of 46% in patients who had at least 12 weeks of follow-up. The combination therapy was well-tolerated and demonstrated a manageable safety profile, with no significant overlapping toxicity between the drugs. These findings support the launch of two new studies: PEAK-1, a Phase 3 trial for immunotherapy-experienced clear cell renal cell carcinoma (ccRCC) patients, and eVOLVE-RCC02, a Phase 1b/3 trial for first-line ccRCC patients. Arcus Biosciences will discuss these data further in a conference call scheduled for June 2, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250601016939) on June 01, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540732812"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540732812\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540732812?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-01 22:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540732812","market":"nz","top_or_hot":-1,"title":"Arcus Biosciences Announces Promising Initial Data for Casdatifan Plus Cabozantinib in Metastatic Kidney Cancer, Prepares to Launch Phase 3 PEAK-1 Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Arcus Biosciences Announces Promising Initial Data for Casdatifan Plus Cabozantinib in Metastatic Kidney Cancer, Prepares to Launch Phase 3 PEAK-1 Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/RCUS\">Arcus Biosciences Inc.</a> has announced initial data from the ARC-20 study, which evaluated the combination of casdatifan and cabozantinib in patients with metastatic kidney cancer. The study reported a confirmed overall response rate of 46% in patients who had at least 12 weeks of follow-up. The combination therapy was well-tolerated and demonstrated a manageable safety profile, with no significant overlapping toxicity between the drugs. These findings support the launch of two new studies: PEAK-1, a Phase 3 trial for immunotherapy-experienced clear cell renal cell carcinoma (ccRCC) patients, and eVOLVE-RCC02, a Phase 1b/3 trial for first-line ccRCC patients. Arcus Biosciences will discuss these data further in a conference call scheduled for June 2, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250601016939) on June 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arcus Biosciences Announces Promising Initial Data for Casdatifan Plus Cabozantinib in Metastatic Kidney Cancer, Prepares to Launch Phase 3 PEAK-1 Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArcus Biosciences Announces Promising Initial Data for Casdatifan Plus Cabozantinib in Metastatic Kidney Cancer, Prepares to Launch Phase 3 PEAK-1 Study\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-01 22:45</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Arcus Biosciences Announces Promising Initial Data for Casdatifan Plus Cabozantinib in Metastatic Kidney Cancer, Prepares to Launch Phase 3 PEAK-1 Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/RCUS\">Arcus Biosciences Inc.</a> has announced initial data from the ARC-20 study, which evaluated the combination of casdatifan and cabozantinib in patients with metastatic kidney cancer. The study reported a confirmed overall response rate of 46% in patients who had at least 12 weeks of follow-up. The combination therapy was well-tolerated and demonstrated a manageable safety profile, with no significant overlapping toxicity between the drugs. These findings support the launch of two new studies: PEAK-1, a Phase 3 trial for immunotherapy-experienced clear cell renal cell carcinoma (ccRCC) patients, and eVOLVE-RCC02, a Phase 1b/3 trial for first-line ccRCC patients. Arcus Biosciences will discuss these data further in a conference call scheduled for June 2, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250601016939) on June 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250601:nNDL15K0ZQ:1","article_id":"2540732812","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540732812","pubTimestamp":1748789119,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Arcus Biosciences Announces Promising Initial Data for Casdatifan Plus Cabozantinib in Metastatic Kidney Cancer, Prepares to Launch Phase 3 PEAK-1 Study. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via Business Wire  on June 01, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Arcus Biosciences公布Casdatifan联合Cabozantinib治疗转移性肾癌的有希望的初始数据，准备启动3期PEAK-1研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HPR.AU":0.9,"RCUS":0.9},"content_text":"Arcus Biosciences Announces Promising Initial Data for Casdatifan Plus Cabozantinib in Metastatic Kidney Cancer, Prepares to Launch Phase 3 PEAK-1 Study\n    \n\nArcus Biosciences Inc. has announced initial data from the ARC-20 study, which evaluated the combination of casdatifan and cabozantinib in patients with metastatic kidney cancer. The study reported a confirmed overall response rate of 46% in patients who had at least 12 weeks of follow-up. The combination therapy was well-tolerated and demonstrated a manageable safety profile, with no significant overlapping toxicity between the drugs. These findings support the launch of two new studies: PEAK-1, a Phase 3 trial for immunotherapy-experienced clear cell renal cell carcinoma (ccRCC) patients, and eVOLVE-RCC02, a Phase 1b/3 trial for first-line ccRCC patients. Arcus Biosciences will discuss these data further in a conference call scheduled for June 2, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250601016939) on June 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}